Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 27 Issue 9, September 2021

Volume 27 Issue 9

Frontline combination therapy in nasopharyngeal carcinoma

Rui-Hua Xu and colleagues at Sun Yat-sen University Cancer Center, in Guangzhou (China), report interim results of the phase 3 randomized JUPITER-02 trial evaluating the frontline anti-PD-1 antibody toripalimab in combination with standard chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma. The watercolor displays a mountainous landscape at sunrise that transforms into the silhouette of a face, illustrating the combination of art and medicine. A bright red sun rising over the nose-like peak symbolizes the hope brought forth by a new treatment for patients with advanced nasopharyngeal carcinoma, who have limited therapeutic options available.

See Rui-Hua Xu and colleagues

Image credit: Shanghai Junshi Biosciences Cover design: Marina Spence


  • Editorial |

    Scientific and medical research conducted in space can bring benefits for all humankind, but this will require commercial space flight companies to embrace open data principles.

News Feature

  • News Feature |

    Tracking the coronavirus SARS-CoV-2, developing treatments and testing vaccines have relied on access to the health data of millions of people. This massive trove could be used to understand other diseases, but not everyone is convinced.

    • Marion Renault


World View

  • World View |

    Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.

    • Jeffrey Cummings
  • World View |

    Lack of rigor in approving aducanumab for Alzheimer’s disease may lead to serious harm.

    • Joel S. Perlmutter


News & Views

  • News & Views |

    Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.

    • Meagan E. Deming
    • Kirsten E. Lyke
  • News & Views |

    Machine learning applied to electronic medical records can be used to create personalized lab-test reference ranges and to quantify disease risk, which will pave the way for precision medicine in clinical care.

    • Alice Tang
    • Tomiko Oskotsky
    • Marina Sirota
  • News & Views |

    The first preliminary evidence that in vivo gene editing in a clinical setting is feasible with no early signs of severe adverse events comes from an ongoing clinical trial to treat transthyretin amyloidosis, a fatal monogenetic disease.

    • Hildegard Büning
    • Axel Schambach

Review Articles

Brief Communications



Quick links